Skip to main content

Advertisement

SpringerLink
Log in

Marginal Zone Lymphoma: State-of-the-Art Treatment

  • Lymphoma (DO Persky, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Despite being the second most common indolent non-Hodgkin’s lymphoma (iNHL), marginal zone lymphoma (MZL) remains largely understudied, and given its underlying disease heterogeneity, it is challenging to define a single treatment approach for these patients. For localized disease, local therapy is recommended such as triple therapy for H. pylori in gastric extranodal MZL, splenectomy for splenic MZL, and radiotherapy for nodal MZL. For disseminated disease with low tumor burden, a watch and wait or single-agent rituximab can be used. However, for symptomatic disease, a similar approach to follicular lymphoma (FL) can be used with chemoimmunotherapy approaches such as bendamustine and rituximab. High FDG uptake is not common in MZL and is not diagnostic by itself of transformation to high-grade lymphoma but informs the choice of the site to be biopsied. Transformation into a large B cell lymphoma is treated with R-CHOP-like regimens. Patients with relapsing disease after at least one CD20-based therapy have several recently approved chemotherapy-free options including B cell receptor inhibitors such ibrutinib (approved specifically in MZL) and immunomodulatory agents such as lenalidomide and rituximab (FDA approved in MZL and FL). Phosphoinositide 3-kinase (PI3K) inhibitors have shown excellent activity in iNHL, specifically in MZL, with breakthrough designation status for copanlisib and umbralisib, allowing off label use of this class of agents in clinical practice. With the availability of prospective clinical trials using chemo-free approaches, specifically those targeting abnormal signaling pathways activated in MZL tumors and its microenvironment, treating physicians are encouraged to enroll patients on these clinical trials in order to better understand the underlying biology, mechanisms of response, and resistance to current therapies and help design future rationale combination strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Maes B, De Wolf-Peeters C. Marginal zone cell lymphoma--an update on recent advances. Histopathology. 2002;40(2):117–26.

    Article  CAS  PubMed  Google Scholar 

  2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol. 1998;16(8):2780–95.

    Article  CAS  PubMed  Google Scholar 

  3. Bertoni F, Coiffier B, Salles G, Stathis A, Traverse-Glehen A, Thieblemont C, et al. MALT lymphomas: pathogenesis can drive treatment. Oncology (Williston Park). 2011;25(12):1134–42.

    Google Scholar 

  4. Thieblemont C. Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. Hematology Am Soc Hematol Educ Program. 2017;2017(1):371–8.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood. 2016;127(17):2082–92.

    Article  CAS  PubMed  Google Scholar 

  6. Du MQ. MALT lymphoma: genetic abnormalities, immunological stimulation and molecular mechanism. Best Pract Res Clin Haematol. 2017;30(1–2):13–23.

    Article  PubMed  Google Scholar 

  7. Inagaki H. Mucosa-associated lymphoid tissue lymphoma: molecular pathogenesis and clinicopathological significance. Pathol Int. 2007;57(8):474–84.

    Article  CAS  PubMed  Google Scholar 

  8. Perrone S, D'Elia GM, Annechini G, Pulsoni A. Infectious Aetiology of marginal zone lymphoma and role of anti-infective therapy. Mediterr J Hematol Infect Dis. 2016;8(1):e2016006.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Sriskandarajah P, Dearden CE. Epidemiology and environmental aspects of marginal zone lymphomas. Best Pract Res Clin Haematol. 2017;30(1–2):84–91.

    Article  PubMed  Google Scholar 

  10. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of helicobacter pylori. Lancet. 1993;342(8871):575–7.

    Article  CAS  PubMed  Google Scholar 

  11. Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell'Oro S, Fleischhauer K, et al. Evidence for an association between chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;96(8):586–94.

    Article  PubMed  Google Scholar 

  12. Garbe C, Stein H, Dienemann D, Orfanos CE. Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol. 1991;24(4):584–90.

    Article  CAS  PubMed  Google Scholar 

  13. Lecuit M, Suarez F, Lortholary O. Immunoproliferative small intestinal disease associated with campylobacter jejuni. Med Sci (Paris). 2004;20(6–7):638–40.

    Article  Google Scholar 

  14. Salem PA, Nassar VH, Shahid MJ, Hajj AA, Alami SY, Balikian JB, et al. “Mediterranean abdominal lymphoma,” or immunoproliferative small intestinal disease. Part I: clinical aspects. Cancer. 1977;40(6):2941–7.

    Article  CAS  PubMed  Google Scholar 

  15. Salem PA, Estephan FF. Immunoproliferative small intestinal disease: current concepts. Cancer J. 2005;11(5):374–82.

    Article  PubMed  Google Scholar 

  16. Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol. 2007;18(2):346–50.

    Article  CAS  PubMed  Google Scholar 

  17. Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90(2):766–75.

    Article  CAS  PubMed  Google Scholar 

  18. Thieblemont C, Mayer A, Dumontet C, Barbier Y, Callet-Bauchu E, Felman P, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab. 2002;87(1):105–11.

    Article  CAS  PubMed  Google Scholar 

  19. Schreuder MI, van den Brand M, Hebeda KM, Groenen P, van Krieken JH, Scheijen B. Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. J Hematop. 2017;10(3–4):91–107.

    Article  PubMed  Google Scholar 

  20. Heilgeist A, McClanahan F, Ho AD, Witzens-Harig M. Prognostic value of the follicular lymphoma international prognostic index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. Cancer. 2013;119(1):99–106.

    Article  PubMed  Google Scholar 

  21. Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, et al. A MALT lymphoma prognostic index. Blood. 2017;130(12):1409–17.

    Article  CAS  PubMed  Google Scholar 

  22. Alderuccio JP, Zhao W, Desai A, Gallastegui N, Ramdial J, Kimble E, et al. Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution. J Clin Oncol. 2018:JCO1800138.

  23. Conconi A, Franceschetti S, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, Moccia AA, et al. Histologic transformation in marginal zone lymphomasdagger. Ann Oncol. 2015;26(11):2329–35.

    Article  CAS  PubMed  Google Scholar 

  24. Bayerdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of helicobacter pylori infection. MALT Lymphoma Study Group Lancet. 1995;345(8965):1591–4.

    CAS  Google Scholar 

  25. Kim JS, Kang SH, Moon HS, Sung JK, Jeong HY. Clinical outcome of eradication therapy for gastric mucosa-associated lymphoid tissue lymphoma according to H. pylori infection status. Gastroenterol Res Pract. 2016;2016:6794848.

    PubMed  PubMed Central  Google Scholar 

  26. Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012;30(24):2988–94.

    Article  CAS  PubMed  Google Scholar 

  27. Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116(16):3815–24.

    Article  PubMed  Google Scholar 

  28. Lossos IS, Fabregas JC, Koru-Sengul T, Miao F, Goodman D, Serafini AN, et al. Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. Leuk Lymphoma. 2015;56(6):1750–5.

    Article  CAS  PubMed  Google Scholar 

  29. Al Juhaishi T, Yazbeck V. Choosing the right pharmacotherapy for non-Hodgkin's lymphoma: does one size fit all? Expert Opin Pharmacother. 2019;20(7):773–5.

    Article  PubMed  CAS  Google Scholar 

  30. Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, et al. Randomized phase II trial comparing Obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015;33(30):3467–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. •• Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus Chlorambucil versus either Chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35(17):1905–12. First large randomized, 3-arms phase III trial that showed superior efficacy of the combination of chlorambucil and rituxian to single agent alone.

    Article  CAS  PubMed  Google Scholar 

  32. Kang HJ, Kim WS, Kim SJ, Lee JJ, Yang DH, Kim JS, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: consortium for improving survival of lymphoma (CISL) study. Ann Hematol. 2012;91(4):543–51.

    Article  CAS  PubMed  Google Scholar 

  33. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Salar A, Domingo-Domenech E, Panizo C, Nicolas C, Bargay J, Muntanola A, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014;1(3):e104–11.

    Article  PubMed  Google Scholar 

  35. Salar A, Domingo-Domenech E, Panizo C, Nicolas C, Bargay J, Muntanola A, et al. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017;130(15):1772–4.

    Article  CAS  PubMed  Google Scholar 

  36. • Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, et al. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. Br J Haematol. 2018;183(5):755–65. A large phase II trial studying the efficacy of BR specifically in splenic marginal zone lymphoma.

    Article  CAS  PubMed  Google Scholar 

  37. Sehn LH, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081–93.

    Article  CAS  PubMed  Google Scholar 

  38. Herold MHE, Janssens A, et al. Immunochemotherapy with obinutuzumab or rituximab in a subset of patients in the randomised gallium trial with previously untreated marginal zone lymphoma (MZL). Hematol Oncol. 2017;35:146–7.

    Article  Google Scholar 

  39. Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: eastern cooperative oncology group protocol E4402. Br J Haematol. 2016;173(6):867–75.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Troch M, Jonak C, Mullauer L, Puspok A, Formanek M, Hauff W, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009;94(5):738–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. •• Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, et al. AUGMENT: a phase III study of Lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188–99. Randomized, phase 3 trial that led to approval of lenalidomide and rituximab in relapsed/refractory follicular lymphoma and marginal zone lymphomas.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, et al. Lenalidomide plus rituximab (R(2) ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019;185(5):874–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. •• Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–32. Phase 2 trial that lead to the FDA-approval of ibrutinib for patients with relapse/refractory MZ.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. • Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169–78. Phase 2 trial that lead to FDA-breakthrough designation for copanlisib for patients with relapse/refractory MZL.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, et al. DYNAMO: a phase II study of Duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912–22.

    Article  CAS  PubMed  Google Scholar 

  47. Forero-Torres A, Ramchandren R, Yacoub A, Wertheim MS, Edenfield WJ, Caimi P, et al. Parsaclisib, a potent and highly selective PI3Kdelta inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019;133(16):1742–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. • Fowler NSF, Jurczak W, et al. Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: a multicenter, open label, registration directed phase II study. J Clin Oncol. 2019;37:7506. Phase 2 trial that lead to FDA-breakthrough designation for umbralisib for patients with relapse/refractory MZL.

    Article  Google Scholar 

  49. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1932–8.

    Article  PubMed  PubMed Central  Google Scholar 

  51. • Cheson BD, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received Obinutuzumab plus Bendamustine induction and Obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;36(22):2259–66. First randomized phase 3 trial to show improvement in overall survival with maintenance obinutuzumab in patients with rituximab-refractory indolent non-hodgkin’s lymphoma.

    Article  CAS  PubMed  Google Scholar 

  52. Andorsky DJCM, Yacoub A, et al. Magnify: phase IIIb interim analysis of induction R2 followed by maintenance in patients with relapsed/refractory indolent non-Hodgkin lymphoma. ASCO Annual Meeting. 2019.

  53. Davids MSFI. O'Connor OA, et al an integrated safety analysis of the next generation PI3Kδ inhibitor Umbralisib (TGR-1202) in patients with relapsed/refractory lymphoid malignancies. Blood. 2017;130:4037.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Virginia Commonwealth University, 401 College Street, Box 980035, Richmond, VA, 23298, USA

    Ariel Sindel DO, Taha Al-Juhaishi MD & Victor Yazbeck MD, MS

  2. Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA

    Victor Yazbeck MD, MS

Authors
  1. Ariel Sindel DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taha Al-Juhaishi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Victor Yazbeck MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victor Yazbeck MD, MS.

Ethics declarations

Conflict of Interest

Ariel Sindel declares that he has no conflict of interest.

Taha Al-Juhaishi declares that he has not conflict of interest.

Victor Yazbeck has received research funding through grants from Gilead and has received honoraria from Pharmacyclics, Celgene, and Seattle Genetics for service on advisory boards.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sindel, A., Al-Juhaishi, T. & Yazbeck, V. Marginal Zone Lymphoma: State-of-the-Art Treatment. Curr. Treat. Options in Oncol. 20, 90 (2019). https://doi.org/10.1007/s11864-019-0687-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-019-0687-5

Keywords

Search

Navigation